Semaglutide
Semaglutide is the generic drug name that identifies the active pharmaceutical ingredient. Novo Nordisk holds patents on branded drugs, which includes Wegovy ®, Ozempic ®, and Rybelsus ®. Generic versions are not yet available, but “authorized generics” (like Rebound Therapeutics’ version) are emerging in select markets. Ewing Weight Loss Clinic in Reno offers prescriptions for Semaglutide-based weight loss drugs. Contact Us for details, or call: 775-322-3011.
- Semaglutide works by suppressing appetite and slowing gastric emptying.
- Average weight loss: 15-20% of body weight over 68 weeks (with diet/exercise).
- Wegovy ® is FDA-approved specifically for weight loss.
- Ozempic ® (same drug, lower dose) is approved for type 2 diabetes but often prescribed off-label for weight loss.
- Rybelsus ® Oral tablet form for diabetes (less effective for weight loss than injections).
Semaglutide: A Detailed Overview
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a medication originally developed for type 2 diabetes that is now widely used for chronic weight management. It mimics the GLP-1 hormone, which regulates:
- Appetite (reduces hunger and cravings).
- Blood sugar (increases insulin secretion).
- Gastric emptying (slows digestion, promoting fullness).
As previously stated, Semaglutide brand names include:
- Wegovy ® – FDA-approved for obesity (BMI ≥ 30 or ≥ 27 + weight-related conditions).
- Ozempic ® – FDA-approved for type 2 diabetes (often prescribed off-label for weight loss).
- Rybelsus ® – Oral tablet version (for diabetes, less effective for weight loss than injections).
Semaglutide (Wegovy/Ozempic) is a breakthrough obesity treatment offering sustainable, clinically significant weight loss with additional metabolic benefits. Its once-weekly injection and non-stimulant approach make it a preferred choice over older drugs, though cost and supply shortages remain challenges.
Semaglutide Uses:
Weight Loss (Wegovy):
- Adults with obesity (BMI ≥ 30).
- Overweight individuals (BMI ≥ 27) with conditions like hypertension, diabetes, or sleep apnea.
For Diabetes (Ozempic/Rybelsus):
- Type 2 diabetics needing better glycemic control.
Off-Label Use:
- Some doctors may prescribe Ozempic ® for weight loss (same drug as Wegovy, but in lower doses).
When Was Semaglutide Approved?
- Ozempic ® (Diabetes): FDA-approved in 2017.
- Rybelsus ® (Oral): Approved in 2019 (first oral GLP-1 agonist).
- Wegovy ® (Obesity): FDA-approved in June 2021.
How is Semaglutide Administered?
Wegovy, Ozempic, and Rybelsus are available by prescription in the United States. Injections are administered once-weekly for Wegovy and Ozempic, while oral pills are administered daily for Rybelsus.
Why is Semaglutide Popular for Weight Loss?
Unprecedented Efficacy:
- Average weight loss: 15-20% of body weight (vs. 5-10% with older drugs).
- Outperforms phentermine, Qsymia, and Orlistat.
Additional Health Benefits:
- Lowers blood sugar, blood pressure, and cardiovascular risk.
- Reduces food noise (obsessive thoughts about eating).
Non-Stimulant: Unlike phentermine, it doesn’t cause jitteriness or addiction.
How Does Semaglutide Work?
Mechanism of Action:
- Appetite Suppression: Acts on brain receptors to reduce hunger signals.
- Slowed Gastric Emptying: Keeps food in the stomach longer, increasing satiety.
- Insulin Regulation: Boosts insulin release when blood sugar is high.
Dosing (Wegovy for Weight Loss):
- Starts at 0.25 mg/week (to minimize side effects).
- Gradually increases to 2.4 mg/week (maintenance dose).
Side Effects:
- Common: Nausea, diarrhea, constipation, fatigue (usually improves over time).
- Rare but Serious: Pancreatitis, gallbladder issues, thyroid tumor risk (contraindicated for those with a family history of medullary thyroid cancer).
All medicines are for the approved indication for which they are authorized in their local country or region.
Comparison: Wegovy vs. Other Weight Loss Drugs
